Please ensure Javascript is enabled for purposes of website accessibility
Contact us Contact Us
EN
Home > Featured Products > Lipopolysaccharide (LPS) Antibodies

Anti-LPS / Lipopolysaccharide Antibodies

Detect lipopolysaccharide (LPS/endotoxin) with anti-LPS antibodies targeting different structural domains: Lipid A (endotoxic moiety), inner/outer core oligosaccharide, and O-antigen polysaccharide. LPS is the principal virulence factor and pathogen-associated molecular pattern (PAMP) of Gram-negative bacteria, anchored in the outer leaflet of the outer membrane. Upon release from bacterial surfaces, LPS is recognized by the TLR4/MD-2/CD14 receptor complex, triggering MyD88-dependent (NF-κB, AP-1) and TRIF-dependent (IRF3, type I IFN) signaling cascades that drive pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6) and innate immune activation. Our antibodies support endotoxin detection and quantification, TLR4 signaling pathway dissection, sepsis and endotoxemia biomarker research, pharmaceutical endotoxin QC assay development, and microbiome/gut barrier permeability studies. RUO

Structural Domain Targeting Anti-Lipid A antibodies detect the conserved endotoxic moiety across all Gram-negative species. Anti-core LPS antibodies target the conserved inner core (Kdo-heptose region). Anti-O-antigen antibodies provide species- and serotype-specific detection for epidemiological typing and strain discrimination.
TLR4 Signaling Research LPS activates the TLR4/MD-2/CD14 complex, triggering MyD88-dependent and TRIF-dependent inflammatory cascades. Anti-LPS antibodies serve as neutralizing/blocking tools and detection reagents in TLR4 pathway studies, enabling dissection of LPS dose-response, LPS-binding protein (LBP) transfer kinetics, and endotoxin tolerance mechanisms.
Sepsis & Endotoxemia LPS drives the hyperinflammatory response in Gram-negative sepsis through massive cytokine release (cytokine storm). Anti-LPS antibodies enable endotoxin quantification in plasma, tissue, and cell culture samples by ELISA — supporting sepsis biomarker discovery, anti-endotoxin therapy evaluation, and endotoxin clearance pathway research.
Endotoxin Detection & QC Anti-Lipid A antibodies serve as alternatives or orthogonal methods to the LAL (Limulus amebocyte lysate) assay for endotoxin detection in pharmaceutical manufacturing, biologics lot release testing, water quality monitoring, and medical device biocompatibility assessment.
Microbiome & Gut Barrier Detect bacterial translocation and LPS leakage across compromised gut epithelial barriers by IHC and ELISA — supporting intestinal permeability (leaky gut), metabolic endotoxemia in obesity/NAFLD, gut-liver axis research, and dysbiosis-driven inflammatory pathway investigation.

All products manufactured by AtaGenix Laboratories under ISO 9001 & ISO 13485 quality systems.

References

1. Raetz CRH, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem. 2002;71:635-700. DOI

2. Park BS, Song DH, Kim HM, et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature. 2009;458(7242):1191-1195. DOI

3. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-1772. DOI

4. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840-851. DOI

39 product results for "Lipopolysaccharide (LPS) Antibodies"

Options+
Options
Confirm

Quick access

Contact Us

  • +86-27-65523339

  • [email protected]

  • Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China

  • linkedin
  • Ins
  • youtube
  • youtube
Copyright © 2026 abinScience. All Rights Reserved. All Products are for Research Use Only